Merck (MRK) EBIT (2009 - 2026)

Merck has disclosed EBIT across 18 years of filings, most recently posting -$7.7 billion for Q1 2026.

• In Q1 2026, EBIT fell 411.15% year-over-year to -$7.7 billion; the TTM figure through Mar 2026 stood at -$5.5 billion (down 208.46% YoY), while the FY2025 annual figure was $4.7 billion, down 1.22% from the prior year.
• EBIT declined to -$7.7 billion in Q1 2026, from -$2.1 billion in the prior quarter.
• Over the last five years, EBIT for MRK reached as high as $2.9 billion in Q3 2025 and fell as low as -$9.4 billion in Q2 2023.
• The 5-year median for EBIT is $10.0 million (2024), against an average of -$794.4 million.
• Annual changes were most pronounced in 2023 — EBIT plunged 3553.51% — and 2025, when it jumped 28800.0%.
• A 5-year view of EBIT shows it stood at -$368.0 million in 2022, then tumbled by 1519.02% to -$6.0 billion in 2023, then jumped by 105.74% to $342.0 million in 2024, then sank by 723.1% to -$2.1 billion in 2025, then plunged by 262.69% to -$7.7 billion in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$7.7 billion, -$2.1 billion, and $2.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.